SunTrust Banks assumed coverage on shares of Alexion Pharmaceuticals (NASDAQ:ALXN) in a research report report published on Tuesday morning, 24/7 WallStreet reports. The brokerage issued a buy rating and a $125.00 price objective on the biopharmaceutical company’s stock.
ALXN has been the subject of a number of other reports. Bank of America began coverage on Alexion Pharmaceuticals in a research note on Thursday, October 17th. They issued a buy rating for the company. Raymond James lifted their price target on Alexion Pharmaceuticals from $168.00 to $170.00 and gave the stock an outperform rating in a research note on Thursday, October 24th. BidaskClub upgraded Alexion Pharmaceuticals from a sell rating to a hold rating in a research note on Wednesday, September 11th. JPMorgan Chase & Co. began coverage on Alexion Pharmaceuticals in a research note on Wednesday, July 31st. They issued an overweight rating and a $172.00 price target for the company. Finally, Citigroup set a $150.00 price target on Alexion Pharmaceuticals and gave the stock a buy rating in a research note on Friday, August 30th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and sixteen have issued a buy rating to the company. The stock currently has a consensus rating of Buy and an average target price of $157.11.
Shares of ALXN traded up $2.48 during trading hours on Tuesday, hitting $108.37. The stock had a trading volume of 1,743,700 shares, compared to its average volume of 1,678,802. The firm has a market cap of $23.71 billion, a P/E ratio of 15.28, a P/E/G ratio of 1.02 and a beta of 1.65. Alexion Pharmaceuticals has a 12-month low of $92.56 and a 12-month high of $141.86. The company’s fifty day simple moving average is $102.94 and its 200 day simple moving average is $115.01. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.45 and a current ratio of 3.98.
Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings results on Wednesday, October 23rd. The biopharmaceutical company reported $2.79 EPS for the quarter, topping the Zacks’ consensus estimate of $2.47 by $0.32. The business had revenue of $1.26 billion during the quarter, compared to the consensus estimate of $1.24 billion. Alexion Pharmaceuticals had a return on equity of 21.21% and a net margin of 31.05%. The company’s revenue for the quarter was up 23.0% compared to the same quarter last year. During the same period last year, the firm earned $2.02 earnings per share. As a group, sell-side analysts predict that Alexion Pharmaceuticals will post 9.39 earnings per share for the current fiscal year.
Hedge funds have recently modified their holdings of the business. Steward Partners Investment Advisory LLC acquired a new position in Alexion Pharmaceuticals in the second quarter valued at approximately $28,000. Redhawk Wealth Advisors Inc. acquired a new position in Alexion Pharmaceuticals in the second quarter valued at approximately $29,000. Investors Research Corp boosted its stake in Alexion Pharmaceuticals by 52.0% in the third quarter. Investors Research Corp now owns 304 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 104 shares during the period. Ossiam acquired a new position in Alexion Pharmaceuticals in the second quarter valued at approximately $32,000. Finally, Capital Bank & Trust Co boosted its position in shares of Alexion Pharmaceuticals by 355.9% during the second quarter. Capital Bank & Trust Co now owns 269 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 210 shares during the period. Institutional investors own 94.56% of the company’s stock.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.
Further Reading: Dividend Reinvestment Plan (DRIP)
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.